These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Good TJ; Kimura AE; Mandava N; Kahook MY Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430 [TBL] [Abstract][Full Text] [Related]
6. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M; JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991 [TBL] [Abstract][Full Text] [Related]
7. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Frenkel MP; Haji SA; Frenkel RE Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773 [TBL] [Abstract][Full Text] [Related]
14. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
15. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Omay E; Elgin U; Sen E; Yilmazbas P Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098 [TBL] [Abstract][Full Text] [Related]